Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0406810 (
NAME
)
13,345
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Plants containing aristolochic acids (AA) are nephrotoxins.
Glycine N-methyltransferase
(
GNMT
) acts to bind environmental toxins such as benzo(a)pyrene and aflatoxin B1, translocate into nucleus, and alter hepatic metabolism. This study aims to determine the role of
GNMT
in AA-induced nephropathy. We established an AA nephropathy mouse model and found that AA type I (AAI)-induced nephropathy at a lower concentration in male than in female mice, implying sex differences in AAI resistance. Microarray analysis and AAI-treated mouse models showed that
GNMT
moderately reduced AAI-induced nephropathy by lowering the upregulated level of NQO1 in male, but significantly improved the nephropathy additionally by increasing Cyp3A44/3A41 in female. The protective effects of
GNMT
were absent in female
GNMT
knockout mice, in which re-expression of hepatic
GNMT
significantly decreased AAI-induced nephropathy. Mechanism-wise, AAI enhanced
GNMT
nuclear translocation, resulting in
GNMT
interaction with the promoter region of the genes encoding Nrf2 and
CAR
/PXR, the transcription factors for NQO1 and CYP3A44/3A41, respectively. Unlike the preference for Nrf2/NQO1 transcriptions at lower levels of
GNMT
, overexpression of
GNMT
preferred
CAR
/PXR/CYP3A44/3A41 transcriptions and alleviated kidney injury upon AAI treatment. In summary, hepatic
GNMT
protected mice from AAI nephropathy by enhancing
CAR
/PXR/CYP3A44/3A41 transcriptions and reducing Nrf2/NQO1 transcriptions.
...
PMID:Glycine N-methyltransferase inhibits aristolochic acid nephropathy by increasing CYP3A44 and decreasing NQO1 expression in female mouse hepatocytes. 2972 48